Table 4. Clinicopathological characteristics of matched patients with synchronous liver metastases undergoing simultaneous or colorectal-first treatment.
| Simultaneous (n = 70) | Colorectal first (n = 70) | P-value | |
|---|---|---|---|
| Patient characteristics | |||
| Mean age ± SD | 62.2 ± 11.6 | 62.3 ± 9.0 | 0.947 |
| Male gender | 37 (52.9%) | 34 (48.6%) | 0.720 |
| Extent of liver surgery | 0.475 | ||
| ≥3 segments | 25 (35.7%) | 27 (38.6%) | |
| 1 or 2 segments | 13 (18.6%) | 14 (20.0%) | |
| RFA or wedge resection | 32 (45.7%) | 29 (41.4%) | |
| RFA | 0.424a | ||
| RFA as part of treatment | 30 (42.9%) | 25 (35.7%) | |
| • RFA + resection | 19 (29.9%) | 11 (15.7%) | |
| • Only RFA | 11 (15.7%) | 20.0%) | |
| Of which percutaneous | 0 | 10 (14.3%) | |
| Characteristics tumor | |||
| Low clinical risk score (0–2)[21] | 37 (52.9%) | 36 (51.4%) | 1.000 |
| Diam. CRLM in cm (median ± IQR) | 2.5 ± 2.5 | 3.0 ± 3.5 | 0.106 |
| Neoadjuvant chemotherapy | 35 (50.0%) | 32 (45.7%) | 0.690 |
| Primary tumor at rectal site | 36 (51.4%) | 34 (48.6%) | 0.832 |
| Bilobar liver disease | 23 (32.9%) | 32 (45.7%) | 0.160 |
Matching was performed based on the characteristics: location of primary tumor, major/minor liver surgery, type of liver procedure, clinical risk score, sex, age and neoadjuvant chemotherapy.
P values were calculated using the paired T test, McNemar test or Wilcoxon signed rank test.
a RFA vs. no RFA in simultaneous vs. colorectal-first treatment.